A first-in-human, prospective feasibility trial of a next-generation, shear-responsive, liquid embolic… | ScholarDeck

Paper

A first-in-human, prospective feasibility trial of a next-generation, shear-responsive, liquid embolic biomaterial, NeoCast.

New research · Neurology

Journal of neurointerventional surgery · 4w

StudyJournal of neurointerventional surgery· Aug 2026

A first-in-human, prospective feasibility trial of a next-generation, shear-responsive, liquid embolic biomaterial, NeoCast.

Lee-Anne Slater, Laetitita de Villiers, Adam S Arthur … David Fiorella

Read paper

NeurologyStudyQ1IF 4.6

NeoCast embolization achieved 89% average devascularization of brain tumors before surgery.

A first-in-human, prospective feasibility trial of a next-generation, shear-responsive, liquid embolic biomaterial, NeoCast.

Lee-Anne Slater … David Fiorella

Journal of neurointerventional surgery · Aug 2026 · Q1 in Neurology

Background

NeoCast TM is a solvent-free, non-adhesive biomaterial engineered to achieve microvascular occlusion.

Methods

EMBO-01 was an open-label, multicenter, prospective, externally monitored, and core lab adjudicated clinical trial.

Results

89±7%

most of each tumor's blood supply was cut off before surgery

More results

NeoCast achieved occlusion in all targeted vessels for all subjects.

There were no adverse events or device deficiencies during embolization.

The average NeoCast injection volume was 0.68±0.28 mL with an average injection time of 7.8±6.4 min.

More results

Tumor resection was complete in all subjects, with an average estimated blood loss of 240±164 mL and average total surgery time of 167±75 min.

“

Conclusion

This first-in-human study provides evidence that NeoCast can be used to reproducibly and safely achieve substantial preoperative devascularization of brain tumors supplied by the middle meningeal artery.

Read paper

0 comments

No comments yet. Be the first.

ScholarDeck.

Join the discussion on this paper

Create your profile

Related papers

Latest Foundational

Cohort Study

87.0% sensitivity

correctly flags most demyelinating cases, fewer are missed

Systematic Review

0.84

TMS correctly flags 84% of patients who go on to regain good arm use

Randomized Trial

Five of 10

half regained voluntary knee and ankle movement against gravity with stimulation

Randomized Trial

96.4%

nearly all patients had meaningfully better swallowing on imaging after injection therapy

Cohort Study

66%

12 of 18 neuromonitoring alerts occurred with neck extension before incision.

Cohort Study

odds ratio 27.2

Electromyography-confirmed radiculopathy makes coexisting multifidus atrophy on magnetic resonance imaging far more likely

Cohort Study

53.3%

over half of alert-negative deficits never recovered by 2 years

Review

54.8%

Transcranial motor evoked potential correctly flagged only about half of true neurological deficits